RNF113A

Across TCGA pan-cancer cohorts, RNF113A Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RNF113A data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher RNF113A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNF113A expression acts as an unfavorable survival marker.

LGG, ESCA, and LUSC are the cancer types where RNF113A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.132	0.830	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.206	0.686	.004	12	view →
LUSC	DFS	Median	III,IV	0.079	0.658	<.001	12	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	9	view →
SARC	DFS	Median	All	0.161	0.613	.014	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNF113A–LGG (OS)

Open the LGG breakdown →